Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6478)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Sep 14, 2021 (publication date) through Apr 29, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wu YL, Kumar R, Wang MF, Singh M, Huang JF, Zhu YY, Lin S. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. World J Gastroenterol 2021; 27(34): 5753-5763 [PMID: 34629799 DOI: 10.3748/wjg.v27.i34.5753] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v27/i34/5753.htm |
| Number | Citing Articles |
| 1 |
Panagiotis Theofilis, Aikaterini Vordoni, Rigas G. Kalaitzidis. Metabolic Dysfunction-Associated Fatty Liver Disease in the National Health and Nutrition Examination Survey 2017–2020: Epidemiology, Clinical Correlates, and the Role of Diagnostic Scores. Metabolites 2022; 12(11): 1070 doi: 10.3390/metabo12111070
|
| 2 |
Min-ran Li, Jin-zhong Li, Jie-ying Li, Cun-chuan Wang, Rui-kun Yuan, Li-hong Ye, Yun-yan Liu, Xu-jing Liang, Hai-cong Zhang, Zhi-quan Liu, Dong-yu Zeng, Xue-dong Zhang, De-hua Wang, Jun-qing Li, Tao-yuan Li, Liu Yang, Yang Cao, Yun Pan, Xun-ge Lin, Calvin Q. Pan, Er-hei Dai, Zhi-yong Dong. Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population. Obesity Facts 2023; 16(5): 427 doi: 10.1159/000530845
|
| 3 |
Milena Georgieva, Charilaos Xenodochidis, Natalia Krasteva. Old age as a risk factor for liver diseases: Modern therapeutic approaches. Experimental Gerontology 2023; 184: 112334 doi: 10.1016/j.exger.2023.112334
|
| 4 |
Xiaoning Chen, George Boon-Bee Goh, Jiaofeng Huang, Yinlian Wu, Mingfang Wang, Rahul Kumar, Su Lin, Yueyong Zhu. Validation of Non-invasive Fibrosis Scores for Predicting Advanced Fibrosis in Metabolic-associated Fatty Liver Disease. Journal of Clinical and Translational Hepatology 2022; 10(4): 589 doi: 10.14218/JCTH.2021.00311
|
| 5 |
Naomi Fearon, Dimitri Pournaras. Obesity, Bariatric and Metabolic Surgery. 2022; : 1 doi: 10.1007/978-3-030-54064-7_107-1
|
| 6 |
Anish Preshy, James Brown. A Bidirectional Association Between Obstructive Sleep Apnea and Metabolic-Associated Fatty Liver Disease. Endocrinology and Metabolism Clinics of North America 2023; 52(3): 509 doi: 10.1016/j.ecl.2023.01.006
|
| 7 |
Xiaodan Zhang, Yimei Chen, Huiyu Ye, Zirui Luo, Jiahong Li, Zhishan Chen, Enting Zhang, Wangen Li. Correlation between thyroid function, sensitivity to thyroid hormones and metabolic dysfunction-associated fatty liver disease in euthyroid subjects with newly diagnosed type 2 diabetes. Endocrine 2022; 80(2): 366 doi: 10.1007/s12020-022-03279-2
|
| 8 |
Piero Portincasa, Gyorgy Baffy. Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology. European Journal of Internal Medicine 2024; doi: 10.1016/j.ejim.2024.04.013
|
| 9 |
Joana Rigor, Andreia Diegues, José Presa, Pedro Barata, Daniela Martins-Mendes. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population. Postgraduate Medicine 2022; 134(4): 435 doi: 10.1080/00325481.2022.2058285
|
| 10 |
Ke-Gong Xiong, Kun-Yu Ke, Li-Fang Chen, Jin-Feng Kong, Tai-Shun Lin, Qing-Biao Lin, Su Lin, Yue-Yong Zhu. The impact of metabolic dysfunction–associated fatty liver disease on the prognosis of patients with hepatocellular carcinoma after radical resection. Hepatobiliary & Pancreatic Diseases International 2023; 22(4): 366 doi: 10.1016/j.hbpd.2022.04.001
|
| 11 |
Xiaoning Chen, Zhan Chen, Lingping Jiang, Jiaofeng Huang, Yueyong Zhu, Su Lin. MAFLD is associated with increased all-cause mortality in low cardiovascular-risk individuals but not in intermediate to high-risk individuals. Nutrition, Metabolism and Cardiovascular Diseases 2023; 33(2): 376 doi: 10.1016/j.numecd.2022.11.007
|
| 12 |
Kai En Chan, Tiffany Jia Ling Koh, Ansel Shao Pin Tang, Jingxuan Quek, Jie Ning Yong, Phoebe Tay, Darren Jun Hao Tan, Wen Hui Lim, Snow Yunni Lin, Daniel Huang, Mark Chan, Chin Meng Khoo, Nicholas W S Chew, Apichat Kaewdech, Naichaya Chamroonkul, Yock Young Dan, Mazen Noureddin, Mark Muthiah, Mohammed Eslam, Cheng Han Ng. Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals. The Journal of Clinical Endocrinology & Metabolism 2022; 107(9): 2691 doi: 10.1210/clinem/dgac321
|
| 13 |
Sabhita Shabir Shaikh, Fakhar Ali Qazi-Arisar, Saba Nafay, Sidra Zaheer, Hafeezullah Shaikh, Zahid Azam. Metabolic puzzle: Exploring liver fibrosis differences in Asian metabolic-associated fatty liver disease subtypes. World Journal of Hepatology 2024; 16(1): 54-64 doi: 10.4254/wjh.v16.i1.54
Abstract(111) |
Core Tip(121) |
Full Article(HTML)(788)
|
Full Article with Cover (PDF)-12619K(23)
|
Full Article (Word)-628K(15)
|
Audio-386K(4)
|
Peer-Review Report-233K(27)
|
Answering Reviewers-161K(22)
|
Full Article (PDF)-1874K(39)
|
Full Article (XML)-114K(18)
|
Times Cited (1)
|
Total Visits (2227)
|
Open
|
| 14 |
Tamara Bassal, Maamoun Basheer, Mariana Boulos, Nimer Assy. Nonalcoholic Fatty Liver Disease—A Concise Review of Noninvasive Tests and Biomarkers. Metabolites 2022; 12(11): 1073 doi: 10.3390/metabo12111073
|
| 15 |
Raphaël Decoin, Laura Butruille, Thomas Defrancq, Jordan Robert, Nicolas Destrait, Augustin Coisne, Samy Aghezzaf, Eloise Woitrain, Zouriatou Gouda, Sofia Schino, Cédric Klein, Patrice Maboudou, François Brigadeau, Didier Klug, Andre Vincentelli, David Dombrowicz, Bart Staels, David Montaigne, Sandro Ninni. High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.957245
|
| 16 |
Eda Kaya, Yusuf Yilmaz. Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease. Therapeutic Advances in Endocrinology and Metabolism 2022; 13: 204201882211396 doi: 10.1177/20420188221139650
|
| 17 |
Naomi Fearon, Dimitri J. Pournaras. Obesity, Bariatric and Metabolic Surgery. 2023; : 1005 doi: 10.1007/978-3-030-60596-4_107
|
| 18 |
Randhall B Carteri, Mateus Grellert, Daniela Luisa Borba, Claudio Augusto Marroni, Sabrina Alves Fernandes. Machine learning approaches using blood biomarkers in non-alcoholic fatty liver diseases. Artificial Intelligence in Gastroenterology 2022; 3(3): 80-87 doi: 10.35712/aig.v3.i3.80
|
| 19 |
Jian-Guo Hong, Lun-Jie Yan, Xian Li, Sheng-Yu Yao, Peng Su, Hai-Chao Li, Zi-Niu Ding, Dong-Xu Wang, Zhao-Ru Dong, Tao Li. Comments on validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. World Journal of Gastroenterology 2022; 28(6): 689-692 doi: 10.3748/wjg.v28.i6.689
|
| 20 |
Takako Inoue, Yasuhito Tanaka. Comprehensive Guide to Hepatitis Advances. 2023; : 31 doi: 10.1016/B978-0-323-98368-6.00009-4
|
| 21 |
Shreya C. Pal, Nahum Méndez-Sánchez. Screening for MAFLD: who, when and how?. Therapeutic Advances in Endocrinology and Metabolism 2023; 14: 204201882211456 doi: 10.1177/20420188221145650
|
| 22 |
Goh Eun Chung, Su Jong Yu, Jeong‐Ju Yoo, Yuri Cho, Kyu‐na Lee, Dong Wook Shin, Yoon Jun Kim, Jung‐Hwan Yoon, Kyungdo Han, Eun Ju Cho. Differential risk of 23 site‐specific incident cancers and cancer‐related mortality among patients with metabolic dysfunction‐associated fatty liver disease: a population‐based cohort study with 9.7 million Korean subjects. Cancer Communications 2023; 43(8): 863 doi: 10.1002/cac2.12454
|